MAPT and Alzheimer disease: AD research has been majorly committed to the development of therapies that can reduce aggregates of toxic forms of Aβ and tau protein, with several of them having reached Phase III clinical trials (e.g., NGP 555, verubecestat, immunotherapy vaccines such as aducanumab, etc.)[81,83].